Repatha (Evolocumab): Legal and Patent Challenges

FDA Approval History and Initial Label

Repatha entered the U.S. Market on August 27, 2015, after the FDA granted approval under a priority review designation. The original label covered three populations: adults with HeFH, patients with HoFH aged 13 and older, and adults with clinical ASCVD who required additional LDL-C lowering 1. This made evolocumab the first PCSK9 inhibitor to reach U.S. Patients.

The Priority Review Path

The FDA based its initial decision on pooled Phase III data from the PROFICIO clinical program, which enrolled more than 6,000 patients across multiple trials. In LAPLACE-2, evolocumab 140 mg every two weeks reduced LDL-C by 66% to 75% versus placebo when added to statin therapy 2. The magnitude of lipid lowering was consistent across baseline statin intensity.

Amgen filed a Biologics License Application (BLA) in August 2014. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 17-0 (with one abstention) in favor of approval, an unusual level of unanimity for a novel biologic 3.

Initial Label Scope

The 2015 label carried an important limitation: it did not include a cardiovascular outcomes claim. The FDA approved evolocumab as an adjunct to diet and maximally tolerated statin therapy based on LDL-C reduction as a surrogate endpoint. This was standard practice for lipid-lowering agents before outcomes data matured, but it created a reimbursement barrier. Payers argued that without proof of reduced heart attacks or strokes, the $14,000 annual list price was difficult to justify.

The European Medicines Agency (EMA) authorized Repatha one month later, in July 2015, through its Committee for Medicinal Products for Human Use (CHMP), with a similar label restricted to LDL-C lowering 4.

The FOURIER Trial and Cardiovascular Outcomes Expansion

The label gap closed in December 2017 when the FDA approved a supplemental BLA adding a cardiovascular risk reduction indication. This change was driven entirely by the FOURIER trial.

FOURIER Design and Results

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) randomized 27,564 patients with established atherosclerotic disease and LDL-C ≥70 mg/dL on statin therapy to evolocumab or placebo 5. The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median 2.2 years.

The key secondary endpoint of cardiovascular death, MI, or stroke showed a 20% relative reduction (HR 0.80; 95% CI 0.73 to 0.88; P<0.001). Evolocumab lowered LDL-C from a median of 92 mg/dL to 30 mg/dL.

What the Expanded Label Means Clinically

The 2017 label update specified that Repatha reduces the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. The label still does not include a mortality benefit claim, because cardiovascular death alone was not statistically significant in FOURIER. This distinction matters for formulary placement: some payers still require prior authorization documentation showing statin intolerance or inadequate response before covering evolocumab.

Amgen v. Sanofi/Regeneron: The Patent War

No discussion of evolocumab's regulatory field is complete without the patent dispute that reached the Supreme Court. The case reshaped how biologics companies draft and defend antibody patents.

Origins of the Dispute

Amgen held U.S. Patent Nos. 8,829,165 and 8,859,741, which claimed a genus of antibodies that bind to specific residues on the PCSK9 protein and block its interaction with the LDL receptor. These claims were broad enough to cover not just evolocumab but potentially alirocumab (Praluent), the competing PCSK9 inhibitor developed by Sanofi and Regeneron 6.

Amgen sued for patent infringement in 2014, shortly before both drugs reached the market. The core legal question: can a patent claim an entire functional genus of antibodies based on what they do (block PCSK9 binding) rather than disclosing the full structural diversity of antibodies that could accomplish that function?

District Court and Federal Circuit Rulings

A Delaware jury initially found Sanofi/Regeneron liable for infringement but also found the Amgen patents invalid for lack of enablement and written description. On appeal, the Federal Circuit reversed on written description but affirmed the enablement invalidity, ruling that Amgen's patents did not teach a person skilled in the art how to make and use the full scope of claimed antibodies without undue experimentation 7.

The dispute cycled through a second trial and a second Federal Circuit appeal. Each round reinforced the same conclusion. Amgen's specifications disclosed 26 antibody examples, but the claims covered potentially millions of antibody variants.

The Supreme Court Decision (2023)

On May 18, 2023, the U.S. Supreme Court ruled unanimously in Amgen Inc. V. Sanofi et al. that the broad genus claims failed the enablement requirement of 35 U.S.C. §112(a). Justice Gorsuch, writing for the Court, held that Amgen had essentially described a "research assignment" by defining antibodies by their function (binding certain PCSK9 residues) without providing directions that would allow skilled artisans to make and use the full scope of what was claimed.

The Court's opinion drew on historical patent cases dating to incandescent-light-bulb litigation from the 1890s. The practical result: Amgen could not use its genus patents to block alirocumab from the market.

Industry Impact

The ruling sent a clear signal to the biologics industry. Broad functional claims for antibodies, the type that dominated biotech patent portfolios for two decades, are now vulnerable unless the patent specification teaches how to reach every corner of the claimed genus. Companies filing antibody patents after 2023 have shifted toward narrower structural claims and larger sets of disclosed sequences.

"The decision doesn't destroy antibody patents, but it demands that applicants show their work," noted a 2023 analysis in Nature Biotechnology 8. Patent prosecution strategies across oncology, autoimmune, and cardiometabolic biologics have been recalibrated as a direct consequence.

Post-Market Safety Surveillance

Evolocumab's safety profile has been monitored through both the FDA's post-market reporting system and dedicated extension studies. Two signals received the most attention: neurocognitive effects and injection-site reactions.

Neurocognitive Monitoring: The EBBINGHAUS Sub-Study

Early concerns about very low LDL-C levels and potential neurocognitive harm prompted the EBBINGHAUS trial, a pre-specified cognitive sub-study of FOURIER. EBBINGHAUS enrolled 1,974 patients and assessed executive function, memory, and psychomotor speed over a median of 19 months 9.

Results showed no significant difference in cognitive function between evolocumab and placebo, even among patients whose LDL-C dropped below 25 mg/dL. The Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory composite score was the primary endpoint, and it was non-inferior (P=0.85).

The FDA Sentinel System active surveillance program has also tracked neurocognitive adverse event reports for the PCSK9 inhibitor class. Through 2024, no safety signal triggered a label change or Risk Evaluation and Mitigation Strategy (REMS) requirement 10.

Injection-Site Reactions and Immunogenicity

The most common adverse events in the FOURIER trial were injection-site reactions (2.1% evolocumab vs. 1.6% placebo). Anti-drug antibody (ADA) development occurred in 0.3% of patients but was not associated with loss of efficacy or hypersensitivity 5.

Musculoskeletal Complaints and Diabetes Risk

Post-market pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) have flagged myalgia and arthralgia reports, though these are confounded by concurrent statin use. A 2020 meta-analysis of PCSK9 inhibitor trials (N=68,123 across 39 studies) found no statistically significant increase in new-onset diabetes with evolocumab or alirocumab (OR 1.04; 95% CI 0.96 to 1.13) 11.

Label Evolutions and Supplemental Approvals

Repatha's label has undergone multiple revisions since 2015, each reflecting new data or regulatory requirements.

Pediatric HoFH Expansion

In 2017, the FDA approved use in patients aged 13 and older with HoFH, based on the TAUSSIG open-label extension study showing sustained LDL-C reductions of approximately 20% to 30% in this difficult-to-treat population 12.

Device and Formulation Updates

The Pushtronex system (previously SureClick), an on-body infusor delivering 420 mg over approximately 5 minutes, was approved to provide patients with a monthly dosing alternative. The label now includes three delivery devices, each with its own instructions-for-use section. In 2020, Amgen received approval for a 420 mg/3.5 mL single-dose prefilled cartridge for use with the autoinjector.

Biosimilar Field

As of mid-2026, no evolocumab biosimilar has received FDA approval. The Supreme Court's 2023 ruling on genus patents does not directly affect the 12-year exclusivity period for reference biologics under the Biologics Price Competition and Innovation Act (BPCIA). Amgen's reference product exclusivity runs through August 2027. Several manufacturers have disclosed biosimilar development programs in regulatory filings with the EMA.

Pricing, Access, and Payer Dynamics

The regulatory and legal trajectory of Repatha cannot be separated from its pricing history. At launch in 2015, the wholesale acquisition cost (WAC) was approximately $14,100 per year. After intense payer pushback, Amgen reduced the list price to $5,850 in 2018, a 60% cut.

Prior Authorization Requirements

Most U.S. Commercial and Medicare Part D plans require documented evidence of statin intolerance or inadequate LDL-C response before authorizing PCSK9 inhibitor coverage. The American College of Cardiology/American Heart Association 2018 cholesterol guidelines explicitly positioned PCSK9 inhibitors for patients with ASCVD and LDL-C ≥70 mg/dL despite maximally tolerated statin therapy 13.

Net Price Trends

According to SSR Health estimates, evolocumab's net price per patient per year fell below $6,000 by 2022 after rebates. That figure represented a roughly 60% reduction from the net price in 2016. The price trajectory influenced both the Supreme Court patent case and formulary negotiations, as Sanofi/Regeneron had engaged in parallel price cuts for alirocumab.

Current Regulatory Status and Ongoing Monitoring

Evolocumab remains on the market with an active BLA (STN 125522) and no outstanding FDA safety communications as of May 2026. The drug is included in the FDA's Sentinel active risk identification and analysis (ARIA) program for continued monitoring of cardiovascular outcomes in real-world populations 10.

Open-Label Extension Data

The OSLER-1 extension study followed patients for up to 5 years, confirming sustained LDL-C lowering of 55% to 60% with no new safety signals 14. Long-term immunogenicity remained low, with neutralizing antibody incidence below 0.1%.

The 2025 ESC/EAS dyslipidemia guidelines list PCSK9 inhibitors as a Class I recommendation (Level of Evidence A) for very-high-risk patients who do not reach LDL-C targets on maximally tolerated statin plus ezetimibe therapy 15.

Clinicians prescribing evolocumab should obtain baseline LDL-C on maximally tolerated statin therapy, document the clinical indication matching the FDA-approved label, and recheck lipid panels 4 to 12 weeks after initiation to confirm response.